All In Biotech

Drug Trial Radar · NCT00312806

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks

Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Planned (sponsor's estimate)

Start

May 2006

Primary completion

Mar 2007

Study completion Jul 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Apr 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • PantoprazoleDrug

    Pantoprazole 40 mg o.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™Time frame: 8 weeks

Locations

186 sites in 22 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed

    Buenos Aires, Argentina

  • Altana Pharma/Nycomed

    Buenos Aires, Argentina

  • Altana Pharma/Nycomed

    Buenos Aires, Argentina

  • Altana Pharma/Nycomed

    La Plata, Argentina

  • Altana Pharma/Nycomed

    Bedford Park SA, Australia

  • Altana Pharma/Nycomed

    Bondi Junction, Australia

  • Altana Pharma/Nycomed

    Fitzroy, Australia

  • Altana Pharma/Nycomed

    Footscray, Australia

  • Altana Pharma/Nycomed

    Fremantle, WA, Australia

  • Altana Pharma/Nycomed

    Kippa_ring, Australia

  • Altana Pharma/Nycomed

    Melbourne, Australia

  • Altana Pharma/Nycomed

    NSW, Australia

  • Altana Pharma/Nycomed

    Penrith, NSW, Australia

  • Altana Pharma/Nycomed

    Phrahran, Australia

  • Altana Pharma/Nycomed

    Deutschlandsberg, Austria

  • Altana Pharma/Nycomed

    Feldbach, Austria

  • Altana Pharma/Nycomed

    Graz, Austria

  • Altana Pharma/Nycomed

    Krems A. D. Donau, Austria

  • Altana Pharma/Nycomed

    Lilienfeld, Austria

  • Altana Pharma/Nycomed

    Sankt Pölten, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Bouge, Belgium

  • Altana Pharma/Nycomed

    Brussels, Belgium

  • Altana Pharma/Nycomed

    Brussels, Belgium

  • Altana Pharma/Nycomed

    Brussels, Belgium

  • Altana Pharma/Nycomed

    Brussels, Belgium

  • Altana Pharma/Nycomed

    Edegem, Belgium

  • Altana Pharma/Nycomed

    Eupen, Belgium

  • Altana Pharma/Nycomed

    Ghent, Belgium

  • Altana Pharma/Nycomed

    Jette, Belgium

  • Altana Pharma/Nycomed

    Kortrijk, Belgium

  • Altana Pharma/Nycomed

    Leuven, Belgium

  • Altana Pharma/Nycomed

    Merksem, Belgium

  • Altana Pharma/Nycomed

    Ostend, Belgium

  • Altana Pharma/Nycomed

    Saint Niklaas, Belgium

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.